Ethnic Variations in Cardiovascular and Renal Outcomes From Newer Glucose‐Lowering Drugs: A Meta‐Analysis of Randomized Outcome Trials

BACKGROUND: Hispanic populations are more likely to develop diabetes and its related diseases than non‐Hispanic White populations. Little evidence exists to support whether the cardiovascular and renal benefits of sodium‐glucose cotransporter 2 inhibitors and glucagon‐like peptide‐1 receptor agonist...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Huilin, Chen, Weihan, Bian, Jiang, O'Neal, LaToya J., Lackland, Daniel T., Schatz, Desmond A., Guo, Jingchuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227303/
https://www.ncbi.nlm.nih.gov/pubmed/37158069
http://dx.doi.org/10.1161/JAHA.122.026791
Descripción
Sumario:BACKGROUND: Hispanic populations are more likely to develop diabetes and its related diseases than non‐Hispanic White populations. Little evidence exists to support whether the cardiovascular and renal benefits of sodium‐glucose cotransporter 2 inhibitors and glucagon‐like peptide‐1 receptor agonists are generalizable to the Hispanic populations. METHODS AND RESULTS: We included the cardiovascular and renal outcome trials (up to March 2021) that reported the major adverse cardiovascular events (MACEs), cardiovascular death/hospitalization for heart failure, and composite renal outcomes by ethnicity in individuals with type 2 diabetes (T2D), calculated pooled hazard ratios (HRs) with 95% CIs using fixed‐effects models, and tested the differences between Hispanic and non‐Hispanic populations (P for interaction [P (interaction)]). In 3 sodium‐glucose cotransporter 2 inhibitor trials, there was a statistically significant difference between Hispanic (HR, 0.70 [95% CI, 0.54–0.91]) and non‐Hispanic (HR, 0.96 [95% CI, 0.86–1.07]) groups in treatment effects on MACE risk (P (interaction)=0.03), except for risks of cardiovascular death/hospitalization for heart failure (P (interaction)=0.46) and composite renal outcome (P (interaction)=0.31). In 5 glucagon‐like peptide‐1 receptor agonist trials, there was no statistically significant difference in treatment effect on MACE risk between Hispanic (HR, 0.82 [95% CI, 0.70–0.96]) and non‐Hispanic (HR, 0.92 [95% CI, 0.84–1.00]) populations (P (interaction)=0.22). In 3 dipeptidyl peptidase‐4 inhibitor trials, the HR for MACE risk appeared greater in Hispanic (HR, 1.15 [95% CI, 0.98–1.35]) than non‐Hispanic (HR, 0.96 [95% CI, 0.88–1.04]) populations (P (interaction)=0.045). CONCLUSIONS: Compared with non‐Hispanic individuals, Hispanic individuals with T2D appeared to obtain a greater benefit of lowered MACE risk with sodium‐glucose cotransporter 2 inhibitors.

Ejemplares similares